Sentiment for Haemonetics Corp (NYSE:HAE)
Haemonetics Corp (NYSE:HAE) institutional sentiment decreased to 0.83 in Q2 2019. Its down -0.10, from 0.93 in 2019Q1. The ratio worsened, as 98 hedge funds started new or increased stock positions, while 118 sold and decreased their stock positions in Haemonetics Corp. The hedge funds in our partner’s database now hold: 48.38 million shares, down from 48.86 million shares in 2019Q1. Also, the number of hedge funds holding Haemonetics Corp in their top 10 stock positions decreased from 1 to 0 for a decrease of 1. Sold All: 36 Reduced: 82 Increased: 57 New Position: 41.
Haemonetics Corporation, a healthcare company, provides hematology products and solutions. The company has market cap of $6.57 billion. The firm operates through five divisions: North America Plasma; Americas Blood Center and Hospital; Europe, Middle East and Africa; Asia Pacific; and Japan. It has a 139.18 P/E ratio. It offers plasma collection and storage products, including PCS brand plasma collection equipment and disposables, plasma collection containers, and intravenous solutions, as well as information technology platforms for plasma clients to manage their donors, operations, and supply chain; Multicomponent Collection System brand apheresis equipment to collect specific blood components integrated from the donor; Automated Cell Processor brand solution to automate the washing and freezing of red cell components; and whole blood collection and processing products.
The stock increased 0.71% or $0.91 during the last trading session, reaching $129.44. About 973,438 shares traded or 164.75% up from the average. Hamonetics Corporation (NYSE:HAE) has risen 26.96% since September 22, 2018 and is uptrending. It has outperformed by 26.96% the S&P500.
Analysts await Hamonetics Corporation (NYSE:HAE) to report earnings on November, 5. They expect $0.71 EPS, up 26.79 % or $0.15 from last year’s $0.56 per share. HAE’s profit will be $36.05 million for 45.58 P/E if the $0.71 EPS becomes a reality. After $0.81 actual EPS reported by Hamonetics Corporation for the previous quarter, Wall Street now forecasts -12.35 % negative EPS growth.
Healthcor Management L.P. holds 1.64% of its portfolio in Hamonetics Corporation for 350,190 shares. Eminence Capital Lp owns 880,219 shares or 1.4% of their US portfolio. Moreover, Jackson Square Partners Llc has 1.22% invested in the company for 1.96 million shares. The Pennsylvania-based Millrace Asset Group Inc. has invested 1.12% in the stock. Picton Mahoney Asset Management, a Ontario – Canada-based fund reported 133,700 shares.
Since January 1, 0001, it had 0 buys, and 6 selling transactions for $15.90 million activity.
Hamonetics Corporation (NYSE:HAE) Ratings Coverage
Ratings analysis reveals 100% of Haemonetics’s analysts are positive. Out of 3 Wall Street analysts rating Haemonetics, 3 give it “Buy”, 0 “Sell” rating, while 0 recommend “Hold”. The lowest target is $11000 while the high is $15000. The stock’s average target of $141 is 8.93% above today’s ($129.44) share price. HAE was included in 6 notes of analysts from April 20, 2019. The rating was upgraded by Raymond James to “Outperform” on Tuesday, May 14. Jefferies maintained the shares of HAE in report on Wednesday, June 19 with “Buy” rating. The firm has “Overweight” rating by Morgan Stanley given on Wednesday, August 7. The stock of Hamonetics Corporation (NYSE:HAE) has “Outperform” rating given on Wednesday, August 7 by Raymond James.
More notable recent Hamonetics Corporation (NYSE:HAE) news were published by: Seekingalpha.com which released: “Haemonetics EPS beats by $0.17, beats on revenue – Seeking Alpha” on August 06, 2019, also Finance.Yahoo.com with their article: “Should You Be Pleased About The CEO Pay At Haemonetics Corporation’s (NYSE:HAE) – Yahoo Finance” published on May 06, 2019, Prnewswire.com published: “Haemonetics to Present at the 17th Morgan Stanley’s Annual Global Healthcare Conference – PRNewswire” on August 28, 2019. More interesting news about Hamonetics Corporation (NYSE:HAE) were released by: Finance.Yahoo.com and their article: “Haemonetics (HAE) Surpasses Q1 Earnings Estimates – Yahoo Finance” published on August 06, 2019 as well as Prnewswire.com‘s news article titled: “Haemonetics Receives FDA Clearance For Expanded Use Of TEG® 6s Hemostasis Analyzer System In Adult Trauma Settings – PRNewswire” with publication date: May 13, 2019.
Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.